GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » Debt-to-EBITDA

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Debt-to-EBITDA : -0.81 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Phoenix Biotech Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.40 Mil. Phoenix Biotech Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Phoenix Biotech Acquisition's annualized EBITDA for the quarter that ended in Sep. 2023 was $-1.72 Mil. Phoenix Biotech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Phoenix Biotech Acquisition's Debt-to-EBITDA or its related term are showing as below:

PBAX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.36   Med: -0.22   Max: -0.22
Current: -0.36

During the past 2 years, the highest Debt-to-EBITDA Ratio of Phoenix Biotech Acquisition was -0.22. The lowest was -0.36. And the median was -0.22.

PBAX's Debt-to-EBITDA is not ranked
in the Diversified Financial Services industry.
Industry Median: 5.345 vs PBAX: -0.36

Phoenix Biotech Acquisition Debt-to-EBITDA Historical Data

The historical data trend for Phoenix Biotech Acquisition's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phoenix Biotech Acquisition Debt-to-EBITDA Chart

Phoenix Biotech Acquisition Annual Data
Trend Dec21 Dec22
Debt-to-EBITDA
N/A -0.22

Phoenix Biotech Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.13 -0.28 -0.19 -0.81

Competitive Comparison of Phoenix Biotech Acquisition's Debt-to-EBITDA

For the Shell Companies subindustry, Phoenix Biotech Acquisition's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phoenix Biotech Acquisition's Debt-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's Debt-to-EBITDA falls into.


Phoenix Biotech Acquisition Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Phoenix Biotech Acquisition's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.65 + 0) / -2.905
=-0.22

Phoenix Biotech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.395 + 0) / -1.72
=-0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

Phoenix Biotech Acquisition  (NAS:PBAX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Phoenix Biotech Acquisition Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » Debt-to-EBITDA
Comparable Companies
NVAC GMFI FHLT ASPA MAQC EFHT MACA BWAQ FORL KYCH PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA
Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103